Increased urinary orosomucoid excretion: A proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 69, Issue 2, 2009, Pages 272-281

  Christiansen, M S ^a   Iversen, K ^a   Larsen, C T ^a   Goetze, J P ^b   Hommel, E ^c   Molvig J ^a   Pedersen, B K ^b   Magid, E ^a   Feldt Rasmussen, B ^b  

^a AMAGER HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

Author keywords

Albuminuria; Inflammation; Intercellular adhesion molecule 1; Orosomucoid; Tissue plasminogen activator; Vasodilation; Ventricular function (left)

Indexed keywords

C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MARKER; OROSOMUCOID; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; IMMUNOASSAY; INFLAMMATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TURBIDIMETRY; URINARY EXCRETION; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; URINE; VASCULAR ENDOTHELIUM;

ADULT; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; MIDDLE AGED; OROSOMUCOID; TISSUE PLASMINOGEN ACTIVATOR;

EID: 65649108650     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802531100     Document Type: Article

References (53)

1. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998;21:1138-45.
2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44 Suppl 2:S14-21.
3. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study. Diabetes Care 2002;25:43-8.
4. Logdberg L, Wester L. Immunocalins: a lipocalin subfamily that modulates immune and inflammatory responses. Biochim Biophys Acta 2000;18(1482):284-97.
5. Schmid K. Human plasma alpha 1-acid glycoprotein -biochemical properties, the amino acid sequence and the structure of the carbohydrate moiety, variants and polymorphism. Prog Clin Biol Res 1989;300:7-22.
6. Poortmans JR, Haralambie G. Biochemical changes in a 100 km run: proteins in serum and urine. Eur J Appl Physiol Occup Physiol 1979;40:245-54.
7. Jensen H, Henriksen K. Proteinuria in non-renal infectious diseases. Acta Med Scand 1974;196:75-82.
8. Pang JX, Ginanni N, Dongre AR, Hefta SA, Opitek GJ. Biomarker discovery in urine by proteomics. J Proteome Res 2002;1:161-9.
9. Nielsen SH, Petersen JS, Magid E. Albuminuria in ischemic heart disease. Scand J Clin Lab Invest Suppl 1999;230:143-52.
10. Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with Type II diabetes. Diabetologia 2002;45:115-20.
11. Christiansen MS, Hommel E, Magid E, Feldt-Rasmussen B. Orosomucoid in urine is a powerful predictor of cardiovascular mortality in normoalbuminuric patients with type 2 diabetes at five years of follow-up. Diabetologia 2005;48: 386-93.
12. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52:1799-805.
13. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acutephase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-92.
14. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;14;340:115-26.
15. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002;51:1157-65.
16. Stehouwer CD, Lambert J, Donker AJ, van HV. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997;34:55-68.
17. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
18. Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BV, Devereux RB. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care 2003;26:2764-9.
19. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus, Geneva: World Health Organization; 1999.
20. Christiansen MS, Blirup-Jensen S, Foged L, Larsen M, Magid E. A particle-enhanced turbidimetric immunoassay for quantitative determination of orosomucoid in urine: development, validation and reference values. Clin Chem Lab Med 2004;42:1168-77.
21. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods. WHO Monograph Series; 1982. pp 162-5.
22. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies. A classification system. Circulation 1960;21:1160-75.
23. Hilsted J, Jensen SB. A simple test for autonomic neuropathy in juvenile diabetics. Acta Med Scand 1979;205:385-7.
24. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
25. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
26. Du Bois D, Du Bois E. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916;17:863-71.
27. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardio-graphic applications for the study of diastolic function. J Am Coll Cardiol 1998;32:865-75.
28. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyo-pathy. Am J Cardiol 1998;82:1071-6.
29. Volk H, Keysser G, Burmester G. Cytokines and cytokine receptors. In: Thomas L, editor. Clinical laboratory diagnostics, use and assessment of clinical laboratory results. 1st edn, Frankfurt am Main: TH-Books; 1998. pp 764-73.
30. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002;48:1035-42.
31. Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, Sogaard P, Rehfeld JF, Jensen JS. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006;27:3004-10.
32. Fournier T, Medjoubi N, Porquet D. Alpha-1-acid glycopro-tein. Biochim Biophys Acta 2000;1482:157-71.
33. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
34. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson KF, Janzon L, Lindgarde F. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 2003;52:442-7.
35. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
36. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106: 506-12.
37. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 2001;286:327-34.
38. Lim SC, Caballero AE, Smakowski P, LoGerfo FW, Horton ES, Veves A. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 1999;22: 1865-70.
39. Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996;28:371-80.
40. Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJ. Circulating cellular adhesion molecules ICAM-1, VCAM-1, P-and E-selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur J Intern Med 2002;13:185-9.
41. Garcia Frade LJ, de la CH, Torrado MC, Lara JI, Cuellar L, Garcia AA. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 1990;59:51-9.
42. Jensen T, Bjerre-Knudsen J, Feldt-Rasmussen B, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989;1:461-3.
43. Held C, Hjemdahl P, Rehnqvist N, Wallen NH, Forslund L, Bjorkander I, Angelin B, Wiman B. Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. J Intern Med 1997;241:59-69.
44. Ihlemann N, Stokholm KH, Eskildsen PC. Impaired vascular reactivity is present despite normal levels of von Willebrand factor in patients with uncomplicated Type 2 diabetes. Diabet Med 2002;19:476-81.
45. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996;27:567-74.
46. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocar-diographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001;24:5-10.
47. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. J Am Med Assoc 2003;289:194-202.
48. Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001;87:320-3.
49. Magid E, Guldager H, Hesse D, Christiansen MS. Monitoring urinary orosomucoid in acute inflammation: observations on urinary excretion of orosomucoid, albumin, {alpha}1-microglobulin, and IgG. Clin Chem 2005;51:2052-8.
50. Sorensson J, Matejka GL, Ohlson M, Haraldsson B. Human endothelial cells produce orosomucoid, an important component of the capillary barrier. Am J Physiol 1999;276(2 Pt 2): H530-4.
51. Johnsson E, Haraldsson B. Addition of purified orosomucoid preserves the glomerular permeability for albumin in isolated perfused rat kidneys. Acta Physiol Scand 1993;147:1-8.
52. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004;20:1559-69.
53. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006;91: 4489-96.